Construction and evaluation of a bioluminescent \textit{Pseudomonas aeruginosa} reporter for use in preservative efficacy testing

Laura Rushton\(^1\)*, Denise Donoghue\(^2\), Matthew Bull\(^1\)†, Peter Jay\(^2\) and Eshwar Mahenthiralingam\(^1\)*

Abstract
Preservative efficacy testing (PET) is a fundamental practice in industrial microbiology used to ensure product shelf-life and quality. To improve on current growth-based PET, bioluminescence was evaluated as a real-time bacterial viability indicator using \textit{Pseudomonas aeruginosa}. Random mutagenesis of an industrial \textit{P} aeruginosa strain with a promoter-less \textit{luxCDABE} mini-Tn5 was used to select a stable reporter (LUX12H5) with an un-altered growth and preservative susceptibility phenotype. Bioluminescence and viability were measured with and without preservatives (isothiazolinones, phenoxyethanol, and dimethyl dimethylol hydantoin) and an antibiotic comparator (ciprofloxacin). In the absence of antimicrobials, a good correlation between bioluminescence and viability \((r^2=0.92)\) was established. However, metabolic inhibition by isothiazolinone preservatives caused a rapid decline in light output that did not correlate to a reduced viability. Conversely, after ciprofloxacin exposure, the decline in viability was greater than that of bioluminescence. A positive attribute of the bioluminescence was the early detection of metabolic recovery and re-growth of preservative injured bacteria. Overall, while initial bioluminescence read-outs were less suited to current PET requirements, it shows promise as an early, direct indicator of bacterial regrowth in the context of long-term evaluation of preservative efficacy.

INTRODUCTION

Antimicrobial preservatives are often incorporated into raw materials and finished industrial products to inhibit proliferation of spoilage or pathogenic microorganisms, which could be introduced during manufacturing or through consumer use. Several factors may influence the activity of the preservative system; consequently, it is difficult to predict its effectiveness in complex formulations and assurance is required by means of a preservative efficacy test (PET) \cite{1}. Standardised methods of PET are published in the European Pharmacopoeia, ISO global standards (11930) and by trade associations such as the Personal Care Products Council. Fundamentally, PET protocols require test samples to be inoculated with microorganisms representative of spoilage or pathogenic contaminants. The inoculated product is then sampled at defined time intervals and microbial survival monitored by re-growth on agar. Preservative systems must meet specified reductions in the viable counts for a range of microorganism over a period of 28 days \cite{2} to comply with PET standards. Current culture-based PET protocols are labour intensive and may lack sensitivity since they require the use of neutralisers to quench preservatives and dilution steps, both of which may diminish microbial numbers and reduce accuracy. Rapid and direct methods of determining microbial viability such as impedance or adenosine triphosphate (ATP) bioluminescence can be used as alternatives to colony counting \cite{1, 3, 4} but have inherent limitations in relation to PET. ATP-bioluminescence for example requires microbial capture and cell lysis to release ATP, with measurement of the bioluminescence generated using luciferin-luciferase reagents \cite{1}. Preservatives and product ingredients may impact greatly
on the exogenous bioluminescence reaction and accuracy is also dependent on efficient ATP extraction [5].

In vivo or whole-cell bioluminescence offers an alternative rapid approach to monitoring the viability of target microorganisms in PET. A well characterised and frequently used bacterial bioluminescent system comes from the terrestrial Gram-negative bacterium *Photorhabdus luminescens* [6]. In the *P. luminescens* luciferase (*lux*) system, all of the genes required for bacterial bioluminescence are organised in a single operon *lux*CDABE [7]; therefore, the addition of an exogenous substrate is not necessary. Bacterial luciferases catalyse the oxidation of reduced flavin mononucleotide (FMNH₂) and a long-chain aldehyde by molecular oxygen, resulting in the emission of light at 490 nm [8]. As the reaction is dependent on the reducing power of FMNH₂, only metabolically active cells can emit light. These systems have been developed into a wide and versatile range of tools for molecular microbiology [6, 9]. In application, recombinant bacteria engineered to express *lux* genes are proven to be sensitive reporters of the real-time effect of antibiotics [10, 11] and biocides [12] on bacterial growth, and are sensitive indicators of cellular viability in experimental systems [9]. Encouragingly, a recent study by Shah and Naseby [13] reported quantification of *Pseudomonas aeruginosa* by whole-cell bioluminescence was to be at least equivalent if not better than traditional plate counting and the ATP determination methods.

The main objective of this study was to explore the applicability of whole-cell bioluminescence for PET in the personal care industry. *P. aeruginosa* was selected as a suitable test species as it is an objectionable, frequently encountered Gram-negative bacterial industrial contaminant [14–16] that is recommended for inclusion by standardised PET protocols [17]. In this study, a stable bioluminescent reporter *P aeruginosa* strain was created by random transposon mutagenesis using mini-Tn5 containing a promoter-less *lux*CDABE operon [18], a system successfully used previously as a reporter of gene expression in the species [19]. The bioluminescence reporter was also constructed within an industry relevant, genome-sequenced *P. aeruginosa* strain, RW110, originally isolated from a contaminated home cleaning product [20]. This approach provided multiple advantages: chromosomal integration of the *lux* genes generated a single-copy reporter construct with greater stability than plasmid-based systems, fitting a fundamental requirement that PET is conducted over a period of weeks; screening a mutant library identified derivatives with stable and high bioluminescence, suitable as *lux* reporters in sensitive assays where low viable cell numbers are detected; and a bespoke reporter could be constructed in a valid industrial *P. aeruginosa* strain which had been used historically in PET. We successfully implemented this novel *P. aeruginosa* *lux* biosensor selection process, and used the resultant reporter strains to evaluate the relationship between bioluminescence and viability as a rapid and direct method of PET.

**METHODS**

**Chemicals and growth media**

Tryptone soya medium (agar, TSA; broth, TSB) and Lysogeny Broth (LB) medium were obtained from Oxoid Ltd. Tetracycline (Tc) and ciprofloxacin (CIP) antibiotics were supplied by Sigma-Aldrich; dimethyl sulfoxide (DMSO) and other analytical grade chemicals were supplied by Fisher Scientific. A minimal basal salts growth medium (BSM) was prepared as described by Rushton et al. [21] without casamino acids. A 3:1 cosmetics grade blend of chloromethylisothiazolinone and methylisothiazolinone (CMIT/MIT), and methylisothiazolinone (MIT) were obtained from Dow Chemical Company, USA; dimethyl dimethylol hydantoin (DMDMH) from Lonza, UK; benzisothiazolinone (BIT) and phenoxyethanol (PH) from Clariant International Ltd, Switzerland. Preservative stock solutions were prepared (in sterile distilled water or DMSO for PH) on the day of use and diluted as required.

**Bacterial strains and construction of bioluminescent P. aeruginosa**

*P. aeruginosa* RW110 an industrial isolate used routinely in PET [20] was utilised in this study. Revival of the frozen isolate was performed on TSA plates at 30 °C. *Escherichia coli* S17-1 Apir donor strain carrying pUTmini-Tn5-*lux*CDABE-Tc was grown on LB containing 10 µg ml⁻¹ Tc at 37 °C. Overnight liquid cultures (3 ml) were inoculated and incubated for 18 h with aeration at an appropriate temperature. Liquid cultures were standardised to an optical density (OD₅₅₀) of one, which equated to approximately 10⁹ c.f.u. ml⁻¹, and were diluted as required. Bacterial stocks were stored at −80 °C in TSB or LB containing 8% v/v DMSO. All experiments were performed as two biological replicates with a range of technical replicates (two to six). The mini-Tn5-*lux*CDABE transposon was delivered into the recipient *P. aeruginosa* RW110 by conjugal mating with the *E. coli* donor as described by Lewenza et al. [19] with the following modifications. Recipient cells were grown at 30°C and heat shocked for 2 min at 42°C prior to biparental mating; donor and recipient were mixed at a ratio of 1:1 on a nitrocellulose filter and incubated on LB agar containing 10 mM MgSO₄ for 24 h at 37°C. To select *P. aeruginosa* transconjugants, the mixture was re-suspended in TSB and plated onto TSA plates containing 200 µg ml⁻¹ Tc. Transconjugants were picked into white 96-well plates containing 200 µl TSB and 50 µg ml⁻¹ Tc, cultured for 24 h on an orbital shaker at 30°C. Bioluminescence was measured before the addition of DMSO (final concentration 8% v/v) and plates were frozen at −80°C for storage.

**Bioluminescent measurements**

Bioluminescent measurements were performed in flat-bottom white 96-well microtitre plates (Greiner, BioOne) using a Tecan Infinite M200 PRO luminometer (Labtech International, UK), with a 1 s integration time. Microtitre plates were dark treated prior to loading and measurements were delayed for 15 min to allow photons trapped in the plastic to dissipate. The instrument level of background ranged from 0 to 20 relative light units (RLU); therefore, a threshold for a bioluminescent light measurement was set as ≥20 RLU. For test measurements, the 200µl samples were staggered (minimum of one well separation) across the microtitre plate.
to reduce crosstalk between wells; non-test or control wells contained 200 µl TSB. The mean RLU of the sample blank was subtracted from each test well and the mean RLU of biological replicates, each with duplicate technical replicates, was then determined for each sample. Observations were first made 1 h after sample inoculation as the instrument was not fitted with an injector system.

Screening bioluminescent *P. aeruginosa* for suitability in PET

*P. aeruginosa* RW110 transposon mutants suitable for application in PET were identified by screening with the following criteria: a high level of bioluminescence (≥5 Log<sub>10</sub> RLU); a stable transcriptional gene fusion maintained in the absence of tetracycline; unaltered growth characteristics; prototrophy; and unchanged preservative susceptibility. The 94 highest light emitters were selected from the initial bioluminescent measurement of the transconjugants and sub-cultured in a white 96-well microtitre plate with an optically clear bottom (Greiner). The wild-type isolate and a sample blank were included on the plate. To determine the stability of transcriptional gene fusion, the sub-group of mutants were replica plated and sub-cultured three times (24 h cultures) in TSB without tetracycline. Measurements of bioluminescence were normalised to the OD<sub>630</sub> of each well (i.e. RLU/ OD<sub>630</sub>) and mutants were ranked in order of light levels. Growth characteristics of the sub-group were determined by turbidometric analysis by transferring 5 µl of an overnight starter culture into a 96-well microtitre plate containing 195 µl of TSB (in triplicate). Growth at 30 °C was monitored over 48 h using a Bioscreen MBR (Labsystems, Finland) as described [21]. The length of lag-phase (hours), growth rate represented by the maximum slope (μ), and maximal growth (OD<sub>420-580</sub>) of each mutant were determined using R statistical software [22] and the Grofit package [23] and compared to the wild-type. To confirm prototrophy, an 18 h culture of the mutants were replica plated onto minimal media (BSM) with 0.4 % (w/v) glucose as the sole carbon source. The susceptibility of the wild-type and mutants to five preservatives frequently used in industry was determined by agar dilution. Then 18 h cultures were replica plated onto TSB (with 3 % w/v purified agar (Oxoid), to reduce the spread of colonies) containing CMIT/MIT at 0.000313–0.005 %, DMDMH at 0.016–0.25 %, MIT at 0.0012–0.019 %, BIT at 0.002–0.038 % and PH at 0.125–0.75 % active. The minimum inhibitory concentration (MIC) was then read after 24 h incubation at 30 °C. The bioluminescence of the top five mutants fulfilling all the selection criteria above, were monitored during culture in TSB over 48 h and normalised to viable counts (c.f.u. ml<sup>−1</sup>) that were determined in parallel (i.e. RLU/ c.f.u. ml<sup>−1</sup>).

Mapping the genomic location of the Tn5 insertion

The insertion sites of the bioluminescent transposon mutants were mapped by genome sequence analysis as follows. Genomic DNA was extracted from pure overnight cultures of the wild-type and the five highest performing mutants, (Table 1) using the Maxwell16 instrument (Promega) and...
a Maxwell 16 Tissue DNA purification kit, according to the manufacturer’s instructions. After RNase A treatment, the DNA was quantified using a Qubit 3.0 fluorometer and eluted to a normalised concentration of 50 ng µl⁻¹ in 10 mM Tris-HCl. DNA was sent for library preparation and sequencing on an Illumina MiSeq at the Earlham Institute (UK). The resulting reads were trimmed with trim-galore v 0.3.5 [24], overlapping reads were extended using FlasH v1.2.2 [25] and assembled using SPAdes v3.0.0 [26]. Annotation of the assembly and prediction of gene function was carried out using Prokka v1.09 [27]. To identify the location of the mini-Tn5 insertion, a local blast database of the genome assemblies was created and compared to the reference genomes *P. aeruginosa* PA01 (GCF_000006765.1) and *P. aeruginosa* PA14 (GCF_000404265.1) using a command line nucleotide (Blastn) search (blast+v2.2.26). Comparison crunch files were generated and Easyfig (v2.1.0) [28] utilised to generate comparative synteny line plots between the genome sequences of *P. aeruginosa* PAO1 and the *P. aeruginosa* RW110 LUX12H5 mutant. To confirm each mini-Tn5 was identical in sequence, a local blast database of the mini-Tn5-luxCDABE sequences from the mutants (Table 2) was also created and compared by Blastn to the mini-Tn5-luxCDABE sequence of mutant LUX12H5 as a reference.

### Table 2. Genomic location of the mini-Tn5- luxCDABE insertion within the five highest performing *P. aeruginosa* mutants

| Mutant ID | Length (bp) | PA01 Locus tag | Predicted function* | Accession no. | Identity (%) to PAO1 genome |
|-----------|-------------|----------------|---------------------|---------------|-----------------------------|
| LUX12H5   | 359         | PA2277         | ArsR protein        | AAG05665.1    | 96.94                       |
| LUX12H8   | 359         | PA2277         | ArsR protein        | AAG05665.1    | 96.94                       |
| LUX1C5    | 1289        | PA0534         | FAD-dependent oxidoreductase | AAG035023.1 | 98.68                       |
| LUX1G4    | 1289        | PA0534         | FAD-dependent oxidoreductase | AAG035023.1 | 98.68                       |
| LUX1C2    | 378         | PA4659         | Probable transcriptional regulator | AAG08046.1   | 99.74                       |

*Homolog in *P. aeruginosa* PA01.

**Bioluminescence assay range and limits of detection**

The relationship between light output and viability was firstly assessed in the absence of antimicrobial. Overnight cultures of the selected reporter mutant were pelleted via centrifugation (1400 g, 10 min) and resuspended in half the volume of fresh medium. A dilution series of the concentrated suspension was prepared in TSB and bioluminescence measured as described above. Viable cells were enumerated by serial dilution and plate count.

**PET**

The following preservatives, commonly used in industry, were evaluated at concentrations corresponding to the maximum EU regulated levels for use in rinse-off personal care products [29]. CMIT/MIT blend 6.25e-06 to 0.0015% w/w active, DMDMH at 0.0015625 to 0.25% w/w active (below the max regulated level of 0.6% active), and PH at 0.125 to 1% v/v active. The PET procedure was modified from standard Pharmacopeia guidelines as follows. Overnight cultures of the bioluminescent reporter strain were prepared and diluted as described above. The test medium was diluted (1:1) with bacterial culture, to achieve the final preservative test concentration and a starting inoculum of approximately 10⁶ c.f.u.
RESULTS

Construction and selection of P. aeruginosa suitable for PET

In total, 1111 luxCDABE mutants were randomly screened and evaluated as reporters. Their bioluminescence after initial culture (with tetracycline) ranged from undetectable ($n=4$) to $6 \log_{10}$ RLU ($n=20$). Mutants with high levels of bioluminescence, at $\geq 5 \log_{10}$ RLU ($n=367$), were ranked in order of light emission, and the top 94 were further characterised to identify those suitable for application in PET. The bioluminescence, growth characteristics and preservative MIC of this 94 sub-group was measured; data for the top five lux reporters is shown in Table 1, with the remaining 89 provided in the supplementary material (Table S1, available in the online version of this article). After three sub-cultures in the absence of tetracycline, 39% of the 94 sub-group were deemed unsuitable, due to inconsistent light emission (bioluminescence decreasing to less than $4 \log_{10}$ RLU for cultures with an OD$_{630}$ >1). The majority of mutants reached a maximal growth (OD$_{630}$, 1.1) and a growth rate ($\mu$) ($\geq0.217$ h$^{-1}$), that was comparable to that of the wild-type (OD$_{630}$, 1.53±0.004, and $\mu$, 0.259±0.008 h$^{-1}$ respectively) (Table S1). However, two mutants with altered lag phases of $4.30 \pm 0.1$ h (LUX1D2) and $0.35 \pm 0.087$ h (LUX12E2) were excluded from selection. An additional mutant (LUX2A1), that failed to grow on a minimal growth medium, was excluded from selection as a putative auxotroph.

Preservative susceptibility of the 94 sub-group was determined by agar dilution method. In total, 76 of the 94 mutants demonstrated altered susceptibility to that of the wild-type (Table S1). Of these, 70 mutants demonstrated a two-fold decrease in the MIC of benzisothiazolinone (BIT), six mutants demonstrated a two-fold increase in MIC of methylviolet (MIT), while five mutants demonstrated a two-fold increase in MIC of diethanol dimethyl hydantoin (DMDMH) (Table S1). None of the 94 mutants demonstrated altered susceptibility to phenoxy ethanol (PH) or the chloromethylsulfothiolzoline and methylviolet spinolzoline blend (CMIT/MIT). Five mutants had altered susceptibility to both MIT and BIT (Table S1). Only one mutant (LUX1D2) demonstrated a gross change in preservative susceptibility with a greater than four-fold decrease in MIC of DMDMH and a two-fold decrease in MIC of BIT (Table 1); this mutant was also determined to have altered growth characteristics.

The top five mutants (Table 1), identified as suitable candidate reporters by the screening process, demonstrated comparable consistent levels of bioluminescence that increased in relation to increasing cell numbers over 48 h (data not shown). Based on the criteria for assessing performance, the P. aeruginosa LUX12H5 mutant was selected as a suitable reporter strain and used in subsequent evaluations.
The long-term stability of the mini-Tn5 insertion within the LUX12H5 mutant was assessed over 6 weeks continuous culture in the absence of tetracycline, via enumeration on TSA plates with and without tetracycline. Levels of bioluminescence were consistent over time and the transposon insertion remained stable in the absence of antibiotic selection. Stable bioluminescence was required for application in PET and maintenance of the reporter as a laboratory strain.

Whole genome sequencing of the top five P. aeruginosa RW110 bioluminescence reporters (Table 1) was performed to map the insertion of the mini-Tn5 construct (Table 2). Insertion of the transposon reporter did not result in genomic rearrangements, and in each case the mini-Tn5 was confirmed to be 100% identical in sequence to the donor construct using BLAST [32]. Two mutants, LUX12H5 and LUX12H8, showed a mini-Tn5 insertion within the same genomic region of P. aeruginosa RW110, disrupting a gene (PA2277) homologous to a predicted ArsR-like protein within the reference strain P. aeruginosa PA01 (Table 2). Genomic examination of region surrounding the mini-Tn5-luxCDABE in LUX12H5 (Fig. 1) demonstrated it had inserted into a locus encoding genes predicted to function in arsenic resistance [33] and was flanked upstream and downstream by transcriptional regulator genes. This confirmed that the Tn5 insertion had not disrupted essential gene(s) in the reporter strain.

**Bioluminescence and viability correlates in the absence of antimicrobials**

In the absence of antimicrobials, the reporter strain produced consistent levels of bioluminescence, and a positive correlation ($r^2=0.9161$) was established between light output and viable counts (Fig. 2). The levels of bioluminescence were a reliable indicator of cell numbers in the experimental system and produced highly accurate light emission-viability correlates down to a minimum limit of detection ($\geq 4 \log_{10}$ CFU ml$^{-1}$; Fig. 2). Between 4 and 10 $\log_{10}$ CFU ml$^{-1}$ there was very limited variance in the light emission readings (Fig. 2). However, the reliability of enumerating cell number by bioluminescence greatly decreased after preservative and/or antibiotic exposure.

**Bioluminescence shows the early and transient effects of isothiazolinone preservatives on bacterial metabolism**

The P. aeruginosa LUX12H5 reporter was subsequently evaluated in a series of tests typical of PET. The effect of low to in-use levels of CMIT/MIT on the bioluminescence and viability of the reporter strain over a period of 2 weeks is shown in Fig. 3. After short exposure times of 1 and 6 h, bioluminescence decreased in relation to increasing preservative concentration: a $1.2 \log_{10}$ reduction in RLU from that of the control at 1 h ($3.43 \log_{10}$ RLU) in the presence of sub-MIC 0.001% active CMIT/MIT (Fig. 3a), ranging up to a 3.28 $\log_{10}$ reduction in RLU in the presence of 0.0015% active CMIT/MIT (Fig. 3a). This early decrease in bioluminescence did not correlate to a reduction in viability for P. aeruginosa LUX12H5 (Fig. 3b), and the same relationship was observed in all ten of the highest performing mutants (listed in Tables 1 and S1). Interestingly, the reduction in bioluminescence was transient for concentrations of CMIT/MIT $\leq 0.0007\%$ active. After 6 h exposure to 0.0001%, and 48 h exposure to 0.0003% CMIT/MIT, bioluminescence was restored to that of the control at 1 h (C.F.U. ml$^{-1}$ had altered by $\leq 1 \log_{10}$) (Fig. 3a). This suggested the recovery of the starting P. aeruginosa inoculum from metabolic inhibition by the sub-lethal preservative concentrations. This response to isothiazolines would not have been apparent by traditional plate count assay.

A similar bioluminescence signal trend was also observed after 24 h exposure to sub-MIC of phenoxyethanol at 0.125 and 0.25% v/v active: RLU decreased respectively by 0.5 and 1.23 $\log_{10}$ from the control at 1 h ($3.08 \log_{10}$ RLU), recovering to 4.89 and 3.93 $\log_{10}$ RLU respectively at 24 h (Fig. 4a). However, metabolic inhibition persisted in the presence of 0.5% v/v phenoxyethanol (MIC) with a mean of $6.99 \pm 0.26 \log_{10}$ CFU ml$^{-1}$ emitting a mean of $1.86 \pm 0.21 \log_{10}$ RLU (Fig. 4).
In contrast, bioluminescence and viability measurements demonstrated the recovery of surviving cells exposed to the MIC of DMDMH (Fig. 5). After 24 h exposure to 0.0313% DMDMH decreased RLU by 2.36 Log$_{10}$ and c.f.u. ml$^{-1}$ by 3.26 Log$_{10}$ from that of the control at 1 h (3.51 Log$_{10}$ RLU and 6.59 c.f.u. ml$^{-1}$) (Fig. 5). This rendered bioluminescence to undetectable levels, and the number of viable cells (3.32±0.6 Log$_{10}$ c.f.u. ml$^{-1}$) close to the lower detection limits of the traditional agar plate count assay (≤1×10$^3$ c.f.u. ml$^{-1}$) [17]. However, after 1 week the surviving cells cultured in the presence of 0.0313% DMDMH had proliferated: levels of bioluminescence and viability were restored and equivalent to that of the control at 168 h (Fig. 5). In this capacity, the assay could provide manufacturers with a means to identify, and consequently avoid, conditions that facilitate the rebound growth of spoilage bacteria. Due to the efficacy of the CMIT/MIT preservative in the experimental system there was a limited range in the number of recovered surviving cells: the starting inoculum was either completely killed or increased from 6.42 to 10.02 Log$_{10}$ c.f.u. ml$^{-1}$ after a period of inhibition, over the weeks of incubation. However, it was apparent that in a system containing preservative, the number of viable cells could not be estimated based on the levels of bioluminescence, as the RLU of preservative exposed cells could be lower than that of equivalent numbers cultured in the absence of preservative (Fig. 3). The discrepancy between bioluminescence and viable cells was particularly problematic during early measurements. For example, 6.57 Log$_{10}$ c.f.u. ml$^{-1}$ exposed to 0.0003% CMIT/MIT for 48 h produced 2.96±0.035 Log$_{10}$ RLU, whereas equivalent numbers of the control produced 3.43±0.002 Log$_{10}$ RLU (Fig. 3). In addition, the sustained absence of detectable bioluminescence was not a reliable indicator of complete kill. For example, inhibitory but sub-lethal concentrations of CMIT/MIT could reduce the light output of the reporter strain to undetectable levels, and the minimum limit of the assay prevented the accurate detection of low numbers of surviving cells.

**Correlation of bioluminescence and viable counts after a ciprofloxacin challenge**

The reduction in bioluminescence but not viability during short-term (<6h) isothiazolinone preservative exposure suggested that the *P. aeruginosa lux* reporter may reveal the transient effects of an antimicrobial on metabolism. A ciprofloxacin challenge was used to explore whether converse correlations between RLU and viability were observed for an antimicrobial that specifically targets DNA replication as opposed to metabolism (Fig. 6).
7 days at timepoints of 1, 24, and 168 h. Data are shown as the Log antibiotic concentrations were monitored in parallel over a period of luxCDABE (relative light units [RLU]) and (b) viability (c.f.u. ml \(^{-1}\)) of \(P.\ aeruginosa\) mutant lux12H5 challenged with a range of ciprofloxacin antibiotic concentrations were monitored in parallel over a period of 7 days at timepoints of 1, 24, and 168 h. Data are shown as the Log\(_{10}\) transformed mean standard deviation of duplicate experiments. Data for concentrations of 0.01625 and 0.125 µg ml\(^{-1}\) not shown. The dotted line shows the threshold for detectable bioluminescence as ≥1.3 Log\(_{10}\) RLU.

Fig. 6. Reduced viable counts of \(P.\ aeruginosa\) LUX12H5 but persisting bioluminescence in the presence of ciprofloxacin. (a) Bioluminescence (relative light units [RLU]) and (b) viability (c.f.u. ml\(^{-1}\)) of \(P.\ aeruginosa\) luxCDABE mutant lux12H5 challenged with a range of ciprofloxacin antibiotic concentrations were monitored in parallel over a period of 7 days at timepoints of 1, 24, and 168 h. Data are shown as the Log\(_{10}\) transformed mean standard deviation of duplicate experiments. Data for concentrations of 0.01625 and 0.125 µg ml\(^{-1}\) not shown. The dotted line shows the threshold for detectable bioluminescence as ≥1.3 Log\(_{10}\) RLU.

Successful isolation of a stable, chromosomally encoded \(P.\ aeruginosa\) lux reporter

We uniquely used random mini-Tn5-lux mutagenesis to create bespoke bioluminescent mutants of a preservative tolerant \(P.\ aeruginosa\) industrial strain suitable for use in PET. A promoter-less mini-Tn5 derivative carrying the luxCDABE operon was used to select for transcribed lux gene fusions [19] in mutants, with a range of bioluminescent capabilities. The approach also worked as promoter-probe screen, identifying constitutive promoters for use in future \(P.\ aeruginosa\) reporter constructs. Overall, the approach was successful in producing a stable light-emitting biosensor, within a relevant industrial \(P.\ aeruginosa\) strain background, for evaluation in PET. Despite the fact transposon mutagenesis can be used to isolate mutants of disrupted phenotype, few of the mutants within the phenotype evaluated sub-group of 94 (Table S1) demonstrated altered growth characteristics or auxotrophy. The study also demonstrated that mini-Tn5 insertions within \(P.\ aeruginosa\) can be highly stable, with the selected LUX12H5 reporter remaining fully functional over weeks of growth passage in the absence of the transposon-selecting antibiotic. The stability of the selected reporter strain meant its maintenance would not differ from that of other challenge test bacteria. To avoid phenotypic change, the Pharmacopoeia compendia recommend that test organisms are lyophilised or cryogenically stored, and the number of passages from the main stock culture is kept to a minimum with a limit of five. Based on the stability findings of this study, the number of passages for the LUX12H5 reporter should be limited to three.

The majority (77 of 94) of the sub-group demonstrated altered susceptibility to preservatives, with a two-fold alteration in the MIC (Table S1). However, this change was in line with natural variations observed within a culture for this type of phenotypic testing [34]. In contrast, Shah and Naseby [35] reported a drastic increase in susceptibility to benzalkonium chloride (eight-fold reduction in MIC) for a transformed \(P.\ aeruginosa\) with a plasmid borne Lux cassette under a constitutive promoter. Large alterations in preservative MIC or growth rate were not observed with the \(P.\ aeruginosa\) LUX12H5 reporter, suggesting that the chromosomal integration of lux genes may help reduce the metabolic burden of the bioluminescent construct. Only one of the evaluated knockout mutations, LUX1D2, resulted in altered susceptibility to unrelated preservatives BIT and DMDH. In total, 36 of 94 mutants subjected to screening fulfilled the selection criteria for application to PET, indicating that the phenotype and bioluminescent stability of the reporter constructs was a consistent trait that could be identified within the overall mutant bank. Using the same approach to construct bespoke reporters in other Gram-negatives such as \(Burkholderia\) and Enterobacteriaceae with industrial relevance [16] should therefore be feasible.
Applicability of bioluminescence to PET and understanding preservative antimicrobial mechanisms of action

A key requirement for the application of bioluminescence in PET was to establish correlation between light output and viable counts. As acceptance criteria of PET stipulate a reduction in the viability of test organisms, not just the inhibition of growth/metabolism. A strict correlation was established between bioluminescence and viable counts in the absence of preservative (Fig. 2). This finding was consistent with those previously reported in the validation study of bioluminescent P. aeruginosa constructs, constitutively expressing plasmid borne lux genes, as a rapid microbiological quantification tool [13]. Although the range of the bioluminescent assay was impressive at six orders of magnitude, the sensitivity or minimum limit of detection was disappointing at around 4 Log_{10} c.f.u. ml\(^{-1}\). This level of sensitivity failed to comply with published PET acceptance criteria that generally require confirmation of a 99% kill or 4 Log_{10} reductions in the test bacteria over time. Shah and Naseby [13] reported better sensitivity with a lower detection limit of 10^0 c.f.u. ml\(^{-1}\), but this difference may have resulted from technical protocol differences such as the luminometer used, sample volume measured or the point at which they elected to assign their lower limit. Our high-throughput and small volume 96-well system, which was suited to PET, was capable of detecting light signals at 10^1 c.f.u. ml\(^{-1}\) (Fig. 2) but this was deemed to be below a reproducible and accurate threshold. Separating the luxCDABE genes into two smaller functional units, luxAB and luxCDE, may provide a means of improving the performance of the reporter strain, as it has been shown to improve the efficiency of transcription and/or translation of the lux system in other bacteria [36]. However, high expression of luciferase systems has been shown to impaired growth characteristics [6] and may thereby reduce the suitability of the reporter strain for PET.

In this study we evaluated the performance of the P. aeruginosa LUX12H5 bioluminescent reporter in presence of three classes of preservative: multiple isothiazolinones, phenoxethanol and the formaldehyde-releaser DMDMH. Previous studies, examining single agents such as benzalkonium chloride against bioluminescent P. aeruginosa. [35] reported no significant difference between bioluminescence and enumeration by plate count. Benzalkonium chloride predominantly targets the cell wall and membrane in bacteria [37], a mode of action that is unlikely to directly interfere with luminescence. In contrast, isothiazolinone and DMDMH agents are known to have an intracellular mode of action that can impede metabolism and therefore bioluminescence. Although we found that bioluminescence and viable counts failed to correlate after short-term exposures to isothiazolinone preservatives, over the long-term duration of the efficacy test the light output to viability correlation improved. In PET, it is important to evaluate short-term and long-term efficacy with the duration of a full test being 28 days. We also found that cells surviving prolonged exposure to low-levels of preservatives could emit less bioluminescence than cells cultured in the absence of preservative. This made the quantification of the surviving test bacteria by bioluminescence levels alone unreliable.

Discrepancies between the bioluminescence and viable counts of reporter strains have been attributed to, and utilised in resolving, the antimicrobial mechanism of action [10, 38]. In bacteria, isothiazolinones are thought to react chemically with thiol containing cytoplasmic and membrane bound enzymes [39]. The rapid decline in bioluminescence but not viability would suggest that isothiazolinones have an immediate effect on bacterial metabolism and/or specifically energy generating metabolic processes, as bioluminescence is dependent on the reducing power of FMNH\(_2\) and a functioning intracellular biochemistry. The transient effect of sub-lethal concentrations of isothiazolinone on bioluminescence inhibition is not fully understood, it is possible that the preservative was being removed from the cells via efflux. The utility of the bioluminescent reporter strain for discriminating the effects of an antimicrobial on multiplication or metabolism was confirmed following a ciprofloxacin challenge. Exposure to ciprofloxacin, which specifically targets DNA gyrase, resulted in a reversion of the correlation observed for isothiazolinone preservatives: viable counts declined before levels of bioluminescence. This finding was consistent with those previously reported for ciprofloxacin challenged self-bioluminescent P. aeruginosa biofilms [40]. An important limitation of the current research into the applicability of whole-cell bioluminescence to PET is the need to consider the effects of antimicrobial agents/concentrations with a bacteriostatic action, capable of inhibiting cellular metabolism (and consequently light emission) and growth but that do not result in cell death.

Bioluminescence reveals the rebound growth of metabolically active cells after DMDMH exposure

Bacterial rebound growth in product released to trade, also known as the phoenix phenomenon [17], can be extremely costly to manufacturers. The situation is characterised by a decline in viable cell numbers before growth resumes, and can generally be attributed to inadequacies in the preservative system [17]. This study highlighted one of the challenges to formulation scientists. The analysis of bioluminescence and viable counts revealed that DMDMH has a rapid and multifactorial effect on both bacterial metabolism and viability. Even low-levels of DMDMH initially reduced viability to the lower limits of detection by conventional agar plate assays and could therefore wrongly be considered as adequate protection against spoilage over the long-term. However, bioluminescence indicated the metabolic recovery/activity of a small group of cells that had survived DMDMH preservative exposure and were able to proliferate. The DMDMH susceptibility of the surviving population was not reassessed in this study, but previous findings by Rushton et al. [21] suggest that the development/selection of DMDMH resistant organisms in industry is a concern that reinforces the importance of thorough PET.

In summary, random mini-Tn5-lux mutagenesis combined with the systematic screening of the mutant library successfully constructed and identified a bioluminescent phenotype suitable for application in PET. A strong correlation between
light output and viable counts was established in the absence of preservative. However, due to the multi-factorial nature of the evaluated preservatives, and their rapid putative effect on bacterial metabolism, the desired correlation during testing was not reliably observed. In this capacity, lux reporters fall short due to their dependency on active metabolism. Consequently, this methodology would not be suitable as an alternative to culture-based PET. The relationship between light and viability was indicative of the antimicrobial mechanism of action. In this respect, lux reporters can be used to advance the understanding of antimicrobial mechanisms of action. Demonstrating the multi-factorial nature of CMIT/ MIT and DMDMH in disrupting metabolic processes in addition to the characterised interactions they have respectively with thiol groups, or the amide and amino groups of protein molecules [39]. P. aeruginosa LUX12H5 bioluminescent reporter demonstrated the propensity for cells exposed to sub-inhibitory concentrations of DMDMH to recover metabolic activity and actively proliferate as rebound growth.

Funding information
This work was funded by a Technology Strategy Board (now called Innovate UK) Knowledge Transfer Partnership scheme (award KTP8702) with additional funding from Unilever Research and Development, Port Sunlight.

Acknowledgements
The authors would like to acknowledge colleagues at Unilever who reviewed the manuscript but are not responsible for the content of this article: Dr Tom Pointon and Dr Stuart Campbell-Lee. We would like to especially thank Dr Shawn Lewenza of Calgary University for gifiting the recombinant E. coli donor strain.

Author contributions
We describe contributions to the paper using the Credit taxonomy. Conceptualisation: E.M., Data curation: L.R. and E.M., Formal analysis: L.R., Funding acquisition: E.M. and D.D., Investigation: L.R., Methodology: L.R., E.M. and D.D., Project administration: L.R.; Resources: E.M. and D.D., and M.B., Supervision: E.M., D.D. and P.J., Validation: L.R., Visualisation: L.R.; Writing- original draft: L.R.; Writing-review and editing: E.M., D.D., and P.J.

Conflicts of interest
L.R., E.M. and M.B. do not declare any conflicts of interest. Peter Jay and Denise Donoghue declare a conflict of interest as employees of Unilever.

References
1. Kramer M, Sukije-Debeljak H, Kmetec V. Preservative efficacy screening of pharmaceutical formulations using ATP bioluminescence. Drug Dev Ind Pharm 2008;34:547–557.
2. Russell AD. Challenge testing: Principles and practice. Int J Cosmet Sci 2003;25:147–153.
3. Jimenez L. Rapid methods for the microbiological surveillance of pharmaceuticals. PDA J Pharm Sci Technol 2001;55:278–285.
4. Connolly P, Bloomfield SF, Denyer SP. A study of the use of rapid methods for preservative efficacy testing of pharmaceuticals and cosmetics. J Appl Bacteriol 1993;75:456–462.
5. Simpson WJ, Hammond JR. The effect of detersents on firely luciferase reactions. J Biolumin Chemilumin 1991;6:97–106.
6. Waidmann MS, Bleichrodt FS, Laslo T, Riedel CU. Bacterial luciferase-reporters: The Swiss army knife of molecular biology. Bioeng Bugs 2011;2:8–16.
7. Meighen EA. Bacterial bioluminescence: Organization, regulation, and application of the lux genes. FASEB J 1993;7:1016–1022.
8. Wilson T, Hastings JW. Bioluminescence. Annu Rev Cell Biol 1998;14:197–230.
9. Stewart G, Williams P. lux Genes and the applications of bacterial bioluminescence. J Gen Microbiol 1992;138:1289–1300.
10. Parveen A, Smith G, Salisbury V, Nelson SM. Biofilm culture of Pseudomonas aeruginosa expressing lux genes as a model to study susceptibility to antimicrobials. FEMS Microbiol Lett 2001;199:115–118.
11. Beard SJ, Salisbury V, Lewis RJ, Sharpe JA, MacGowan AP. Expression of lux genes in a clinical isolate of Streptococcus pneumoniae: Using bioluminescence to monitor gemifloxacin activity. Antimicrob Agents Chemother 2002;66:538–542.
12. Robinson GM, Tonks KM, Thorn RMS, Reynolds DM. Application of bacterial bioluminescence to assess the efficacy of fast-acting biocides. Antimicrob Agents Chemother 2011;55:5214–5219.
13. Shah N, Naseby DC. Validation of constitutively expressed bioluminescent Pseudomonas aeruginosa as a rapid microbiological quantification tool. Biosensors and Bioelectronics 2015;68.
14. Jimenez L. Microbial diversity in pharmaceutical product recalls and environments. PDA J Pharm Sci Technol 2007;61:383–399.
15. Sutton S, Jimenez L. A review of reported recalls involving microbiological control 2004-2011 with emphasis on FDA considerations of 'objectionable organisms. Am Pharm Rev 2012;15.
16. Cunningham-Oakes E, Weiser R, Pointon T, Mahenthiralingam E. Understanding the challenges of non-food industrial product contamination. FEMS Microbiology Letters 2020;366.
17. Orth DS, Kabara JJ, Denyer SP. Cosmetic and Drug Microbiology. New York, London: Informa Healthcare; 2006.
18. Winson MK, Swift S, Hill PJ, Sims CM, Griesmayr G, et al. Engineering the luxCDBAE genes of Photobacterium luminescens to provide a bioluminescent reporter for constitutive and promoter probe plasmids and mini-Tn5 constructs. FEMS Microbiol Lett 1998;163:193–202.
19. Lewenza S, Falsafi RW, Winsor G, Gooderham WJ, McPhee JB, et al. Construction of a mini-Tn5-luxCDBAE mutant library in Pseudomonas aeruginosa PA01: A tool for identifying differentially regulated genes. Genome Res 2005;15:583–589.
20. Weiser R, Green AE, Bull MJ, Cunningham-Oakes E, Jolley KA, et al. Not all Pseudomonas aeruginosa are equal: Strains from industrial sources possess uniquely large multireplication genomes. Microb Genom 2019;5.
21. Rushton L, Sass A, Baldwin A, Dowson CG, Donoghue D, et al. Key role for efflux in the preservative susceptibility and adaptive resistance of Burkholderia cepacia complex bacteria. Antimicrob Agents Chemother 2013;57:2972–2980.
22. R-Core.Team. In: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2013. https://www.r-project.org/
23. Kahm M, Hasenbrink G, Lichtenberg-Fraté H, Ludwig J, Kschichko M. Golfit: Fitting biological growth curves with R. J Stat Softw 2010;33:1–21.
24. Krueger F. Trim Galore! a wrapper tool around Cutadapt and Fastqc to consistently apply quality and adapter trimming to FASTQ files. 2012. http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/.
25. Magoc T, Salzberg SL. FLASH: Fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011;27:2957–2963.
26. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, et al. Spades: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012;19:455–477.
27. Seemann T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 2014;30:2068–2069.
28. Sullivan MJ, Petty NK, Beatson SA. Easyfig: A Genome Comparison Visualizer. Bioinformatics (Oxford, England), 2011, pp. 1009–1010.
29. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, OJ L 342 22.12.2009. 2009.
30. Lear JC, Maillard JY, Dettmar PW, Goddard PA, Russell AD. Chlo-roxylenol- and triclosan-tolerant bacteria from industrial sources - susceptibility to antibiotics and other biocides. Int Biodeter Biodegr 2006;57:51–56.

31. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48:5–16.

32. Agarwala R, Barrett T, Beck J, Benson DA, Bollin C, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2017;45.

33. Cai J, Salmon K, DuBow MS. A chromosomal ars operon homologue of Pseudomonas aeruginosa confers increased resistance to arsenic and antimony in Escherichia coli. Microbiology 1998;144:2705–2713.

34. Weiser R, Donoghue D, Weightman A, Mahenthiralingam E. Evaluation of five selective media for the detection of Pseudomonas aeruginosa using a strain panel from clinical, environmental and industrial sources. J Microbiol Methods 2014;99:8–14.

35. Shah N, Naseby DC. Efficacy of benzalkonium chloride against bioluminescent P. aeruginosa ATCC9027 constructs. Biosensors and Bioelectronics 2017;97:8–15.

36. Elad T, Almog R, Yagur-Kroll S, Levkov K, Melamed S, et al. Online monitoring of water toxicity by use of bioluminescent reporter bacterial biochips. Environ Sci Technol 2011;45:8536–8542.

37. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbial Rev 1999;12:147–179.

38. Choi SH, Gu MB. A portable toxicity biosensor using freeze-dried recombinant bioluminescent bacteria. Biosens Bioelectron 2002;17:433–440.

39. Denyer SP. Mechanisms of action of antibacterial biocides. Int Biodeter Biodegr 1995;36:227–245.

40. Marques CNH, Salisbury VC, Greenman J, Bowker KE, Nelson SM. Discrepancy between viable counts and light output as viability measurements, following ciprofloxacin challenge of self-bioluminescent Pseudomonas aeruginosa biofilms. J Antimicrob Chemother 2005;56:665–671.

Edited by: J. Cavet and A. Kumar

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.